咨询与建议

看过本文的还看了

相关文献

该作者的其他文献

文献详情 >Management of antiviral drug r... 收藏

Management of antiviral drug resistance in chronic hepatitis B

Management of antiviral drug resistance in chronic hepatitis B

作     者:Ki Bae Bang Hong Joo Kim 

作者机构:Department of Internal Medicine Sungkyunkwan University Kangbuk Samsung Hospital Seoul 110-746 South Korea 

出 版 物:《World Journal of Gastroenterology》 (世界胃肠病学杂志(英文版))

年 卷 期:2014年第20卷第33期

页      面:11641-11649页

核心收录:

学科分类:1004[医学-公共卫生与预防医学(可授医学、理学学位)] 1002[医学-临床医学] 100401[医学-流行病与卫生统计学] 10[医学] 

主  题:Chronic hepatitis B Antiviral resistance Rescue treatment Multidrug resistance Cross resistance 

摘      要:Rescue antiviral treatment for patients with resistance to preexisting nucleos(t)ide analogues remains a clinical challenge. The correct choice of a first-line treatment of high potency and with a high genetic barrier to achieve sustained long-term suppression of viral replication provides the best chance of preventing treatment failure and the emergence of drug resistance. The management of treatment failure and drug resistance requires a precise and accurate clinical and virologic monitoring. Combination treatment with antiviral drugs that belong to different groups is associated with a lower chance of developing resistance to rescue drugs. To guarantee better control of viral replication in patients with drug resistance, the addition of another drug without a cross resistance profile should be given as early as possible, preferably at the time when genotypic resistance emerges. Long-term surveillance for treatment efficacy and possible emergence of drug resistance should be continued to prevent the emergence of multidrug-resistant strains.

读者评论 与其他读者分享你的观点

用户名:未登录
我的评分